仅用于工业应用或科学研究，不可用于人类或动物的临床诊断或治疗，非药用. Vantictumab （OMP-18R5） is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab is being studied against cancers such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma